381 related articles for article (PubMed ID: 29482062)
1. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
2. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
[TBL] [Abstract][Full Text] [Related]
3. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
Kim H; Griffith TS; Panyam J
J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
[TBL] [Abstract][Full Text] [Related]
4. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
5. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
[TBL] [Abstract][Full Text] [Related]
11. Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.
Ding Y; Liu J; Lu S; Igweze J; Xu W; Kuang D; Zealey C; Liu D; Gregor A; Bozorgzad A; Zhang L; Yue E; Mujib S; Ostrowski M; Chen P
J Control Release; 2016 Aug; 236():22-30. PubMed ID: 27297778
[TBL] [Abstract][Full Text] [Related]
12. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.
Smits EL; Cools N; Lion E; Van Camp K; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Cancer Immunol Immunother; 2010 Jan; 59(1):35-46. PubMed ID: 19449004
[TBL] [Abstract][Full Text] [Related]
13. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.
Nuhn L; Vanparijs N; De Beuckelaer A; Lybaert L; Verstraete G; Deswarte K; Lienenklaus S; Shukla NM; Salyer AC; Lambrecht BN; Grooten J; David SA; De Koker S; De Geest BG
Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8098-103. PubMed ID: 27382168
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
[TBL] [Abstract][Full Text] [Related]
16. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
[TBL] [Abstract][Full Text] [Related]
17. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
18. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
Wang Y; Chen K; Wu Z; Liu Y; Liu S; Zou Z; Chen SH; Qu C
Int J Infect Dis; 2014 Dec; 29():31-6. PubMed ID: 25449231
[TBL] [Abstract][Full Text] [Related]
19. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
20. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation.
Mottas I; Bekdemir A; Cereghetti A; Spagnuolo L; Yang YS; Müller M; Irvine DJ; Stellacci F; Bourquin C
Biomaterials; 2019 Jan; 190-191():111-120. PubMed ID: 30415018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]